<i>APC</i> and <i>P53</i> mutations synergise to create a therapeutic vulnerability to NOTUM inhibition in advanced colorectal cancer

Our findings that a single agent targeting the extracellular enzyme NOTUM is effective in treating highly aggressive, metastatic adenocarcinomas in preclinical mouse models and human organoids make NOTUM and its glypican targets therapeutic vulnerabilities in advanced CRC.